English – Page 47 – Alligator Bioscience

2017-08-23

Regulatory

Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017

“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...

2017-08-17

Regulatory

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden – August ...

2017-08-07

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing tumor-directed immunotherapies for canc ...

2017-07-21

Regulatory

Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...

2017-06-12

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing antibody-based pharmaceuticals for canc ...

2017-05-04

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today presented new pre-clinical data on the CD40 agonistic immuno-oncology ...

2017-05-02

Today, on May 2, 2017, an annual shareholders’ meeting was held in Alligator Bioscience AB. A summary of the resolutions adopted follows bel ...

2017-05-02

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017. “In the first quarte ...

2017-04-28

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will present new pre-clinical data on the CD40 agon ...